Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,628

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,628 results for “type safety”

Learn how ShareScore rates datasets ↗
zenodo44/100

Maximum temperature data from thermal safety assessment of type 21700 lithium-ion batteries with NMC, NCA and LFP cathodes by means of Accelerating Rate Calorimetry (ARC)

<p>Data of safety investigation and thermal abuse behavior of commercial type 21700 LIB cells is provided.</p> <p>It has been acquired with Accelerating Rate Calorimetry (ARC), using a Thermal Hazard Technology type ES ARC.</p> <p>Moreover, thermal abuse was done by means of the so-called Heat-Wait-Seek (HWS) test, at different states of charge (SOC) from 0 to 100.</p> <p>Different cathode chemistries are compared (NMC, NCA and LFP), as well as for NCA chemistry, the high energy (HE) and high power (HP) cell design.</p> <p>For each cell, data includes the maximum temperature measured during thermal abuse at the surface on the center of the cell. Additionally, the mean value and standard deviation for each cell type and state of charge is provided.</p> <p>This data is supporting this article in the journal Batteries:</p> <p><a href="https://doi.org/10.3390/batteries9050237">https://doi.org/10.3390/batteries9050237</a></p> <p>Additional supporting material to this article are the exothermal data for thermal abuse, that are published here:</p> <p><a href="https://doi.org/10.5281/zenodo.7707929">https://doi.org/10.5281/zenodo.7707929</a></p> <p>&nbsp;</p>

opencc-by-4.0Apr 2023View details →
zenodo40/100

Dataset: Breaking Type-Safety in Go: An Empirical Study on the Usage of the unsafe Package

<p>This dataset contains all script used in the study, as well as the raw data extracted from the repositories and the&nbsp;processed data used to analyze our RQs in the manuscript &quot;Breaking Type-Safety in Go: An Empirical Study on the Usage of the unsafe Package&quot;.</p> <p>For more information on how to understand the folder structure, scripts, and dataset, please read the README.md.&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p>

opencc-by-4.0May 2020View details →
ClinicalTrials.gov40/100

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

ClinicalTrials.gov study NCT02586805. IPD Sharing: YES. Countries: 7. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

ClinicalTrials.gov study NCT03005288. IPD Sharing: YES. Countries: 2. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

ClinicalTrials.gov study NCT02735044. IPD Sharing: YES. Countries: 24. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

ClinicalTrials.gov study NCT02787551. IPD Sharing: YES. Countries: 9. Publications: 5.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

ClinicalTrials.gov study NCT03930732. IPD Sharing: YES. Countries: 24. Publications: 5.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

ClinicalTrials.gov study NCT02353871. IPD Sharing: YES. Countries: 2. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

ClinicalTrials.gov study NCT05089656. IPD Sharing: YES. Countries: 13. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

ClinicalTrials.gov study NCT03875729. IPD Sharing: YES. Countries: 9. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

ClinicalTrials.gov study NCT02493946. IPD Sharing: YES. Countries: 3. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

ClinicalTrials.gov study NCT02741596. IPD Sharing: YES. Countries: 7. Publications: 5.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

ClinicalTrials.gov study NCT03066609. IPD Sharing: UNDECIDED. Countries: 6. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov40/100

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

ClinicalTrials.gov study NCT04456673. IPD Sharing: YES. Countries: 29. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov study NCT02973321. IPD Sharing: YES. Countries: 8. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

ClinicalTrials.gov study NCT01640951. IPD Sharing: UNDECIDED. Countries: 15. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad36/100

Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model

<p class="MsoNormal"><span>Vagus nerve stimulation is emerging as a promising treatment for type 2 diabetes. Here, we evaluated the ability of stimulation of the vagus nerve to reduce glycaemia in awake, freely moving metabolically compromised rats. A model of type 2 diabetes (n=10) was induced using a high-fat diet and low doses of streptozotocin. Stimulation of the abdominal vagus nerve was achieved by pairing 15 Hz pulses on a distal pair of electrodes </span><span>with high-frequency blocking stimulation (26 kHz, 4 mA) on a proximal pair of electrodes to preferentially produce efferent conducting activity </span><span>(eVNS)</span><span>. </span><span>Stimulation was well tolerated in awake, freely moving rats. During 1 hour of eVNS, glycaemia decreased in 90% of subjects (-1.25±1.25 mM·h, <em>P</em>=0.017), and 2 dB above neural threshold was established as the most effective 'dose' of eVNS (<em>P</em>=0.009). Following 5 weeks of implantation, eVNS was still effective, resulting in significantly decreased glycaemia (-1.7±0.6 mM·h, <em>P</em>=0.003) during 1 hour of eVNS. There were no overt changes in fascicle area or signs of histopathological damage observed in implanted vagal nerve tissue following chronic implantation and stimulation. </span><span>Demonstration of the biocompatability and safety of eVNS in awake, </span><span>metabolically compromised</span><span> animals is a critical first step to establishing this therapy for clinical use. With further development, </span><span>eVNS could be a promising novel therapy for treating type 2 diabetes.</span></p>

opencc-zeroNov 2022View details →
zenodo36/100

The efficacy and safety of meal replacement in patients with type 2 diabetes: a systematic review and meta-analysis

<p>There are supplemental materials for a&nbsp;systematic review and meta-analysis, which studied the efficacy and safety of meal replacement in patients with type 2 diabetes,&nbsp;with a focus on subgroup analysis of variable participant characteristics and MR prescription.</p>

opencc-by-4.0May 2023View details →
ClinicalTrials.gov36/100

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

ClinicalTrials.gov study NCT00900146. IPD Sharing: Not stated. Countries: 14. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

ClinicalTrials.gov study NCT01708902. IPD Sharing: Not stated. Countries: 4. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record